Related Experiment Video
Updated: Mar 15, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
PIK3CA Mutations in Resected Small Cell Lung Cancer
Na Han1,2, Qiao-Yuan Cheng3, Bo Chen4
1Zhejiang Key Laboratory of Diagnosis & Treatment Technology for Thoracic Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
Background:
Despite advances in chemotherapy and radiotherapy in recent decades, the prognosis for small cell lung cancer (SCLC) patients is still poor. Targeted therapies in SCLC must be applied systemically to target not only the primary tumor but also metastases. The phosphatidylinositol 3-kinase (PI3K)/AKT pathways play a key regulatory function in the survival, proliferation, energy metabolism and cellular architecture advantages of malignant cells. The phosphatidylinositol 3-kinase catalytic α (PIK3CA) gene, which encodes the p110α catalytic subunit, plays a key role in the activation of AKT downstream signaling and mammary tumor progression. More than 75% of PIK3CA mutations are clustered in the helical (exon 9) and catalytic domains (exon 20). There have been very few studies reporting the PIK3CA mutations status of patients with SCLC who have undergone surgical treatment in mainland China.
Objectives:
The aim of the study was to investigate the PIK3CA mutation in SCLC.
Material And Methods:
Reverse transcription polymerase chain reaction (RT-PCR) and direct sequencing technology was used to detect the PIK3CA mutation in 14 cases of retrospectively collected SCLC patients who underwent surgical treatment at Zhejiang Cancer Hospital, Hangzhou, PRC, between 2002 and 2010.
Results:
The research revealed no mutations in exons 9 and 20 of the PIK3CA gene. A nucleotide alteration of A1634C (E545A) of exon 9 turned out to be a pseudogene-positive, because the mutation disappeared when near-duplicate detection was employed.
Conclusions:
The incidence of PIK3CA mutation is low in SCLC patients, and the pseudogene-positive alteration of A1634C is prone to occur in exon 9 of PIK3CA mutations in human cancers.
Insights
This study found a low incidence of phosphatidylinositol 3-kinase catalytic α (PIK3CA) gene mutations in small cell lung cancer (SCLC) patients. Researchers identified a common pseudogene alteration in exon 9, emphasizing the need for careful analysis in cancer research.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small cell lung cancer (SCLC) has a poor prognosis despite advances in treatment.
- Targeted therapies require systemic application for primary tumors and metastases.
- The PI3K/AKT pathway is crucial for cancer cell survival and proliferation, with PIK3CA mutations common in other cancers.
Purpose of the Study:
- To investigate the frequency and types of PIK3CA gene mutations in surgically treated SCLC patients.
- To assess the role of PIK3CA mutations in SCLC, particularly in exons 9 and 20.
Main Methods:
- Retrospective analysis of 14 SCLC patient samples treated between 2002 and 2010.
- Detection of PIK3CA mutations using reverse transcription polymerase chain reaction (RT-PCR) and direct sequencing.
- Verification of mutations using near-duplicate detection to rule out pseudogene alterations.
Main Results:
- No PIK3CA mutations were detected in the helical (exon 9) or catalytic (exon 20) domains.
- A nucleotide alteration A1634C (E545A) in exon 9 was identified as a pseudogene-positive result.
- The pseudogene alteration was confirmed to be non-pathogenic through further testing.
Conclusions:
- The incidence of PIK3CA mutations is low in the studied SCLC patient cohort.
- The pseudogene-positive alteration A1634C in exon 9 is a potential pitfall in PIK3CA mutation analysis for human cancers.
- Further research is needed to understand the role of PIK3CA in SCLC pathogenesis.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:38The Ras Gene
Ras is a...